GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Evolus Inc (NAS:EOLS) » Definitions » ROIC %

Evolus (Evolus) ROIC % : -42.37% (As of Dec. 2023)


View and export this data going back to 2018. Start your Free Trial

What is Evolus ROIC %?

ROIC % measures how well a company generates cash flow relative to the capital it has invested in its business. It is also called ROC %. Evolus's annualized return on invested capital (ROIC %) for the quarter that ended in Dec. 2023 was -42.37%.

As of today (2024-04-27), Evolus's WACC % is 11.80%. Evolus's ROIC % is -48.85% (calculated using TTM income statement data). Evolus earns returns that do not match up to its cost of capital. It will destroy value as it grows.


Evolus ROIC % Historical Data

The historical data trend for Evolus's ROIC % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Evolus ROIC % Chart

Evolus Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
ROIC %
Get a 7-Day Free Trial Premium Member Only -96.33 -50.85 -47.68 -67.88 -50.64

Evolus Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
ROIC % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -40.27 -45.18 -55.87 -49.83 -42.37

Competitive Comparison of Evolus's ROIC %

For the Drug Manufacturers - Specialty & Generic subindustry, Evolus's ROIC %, along with its competitors' market caps and ROIC % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Evolus's ROIC % Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Evolus's ROIC % distribution charts can be found below:

* The bar in red indicates where Evolus's ROIC % falls into.



Evolus ROIC % Calculation

Evolus's annualized Return on Invested Capital (ROIC %) for the fiscal year that ended in Dec. 2023 is calculated as:

ROIC % (A: Dec. 2023 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (A: Dec. 2022 ) + Invested Capital (A: Dec. 2023 ))/ count )
=-44.976 * ( 1 - -0.29% )/( (87.883 + 90.279)/ 2 )
=-45.1064304/89.081
=-50.64 %

where

Evolus's annualized Return on Invested Capital (ROIC %) for the quarter that ended in Dec. 2023 is calculated as:

ROIC % (Q: Dec. 2023 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (Q: Sep. 2023 ) + Invested Capital (Q: Dec. 2023 ))/ count )
=-38.04 * ( 1 - -0.9% )/( (90.889 + 90.279)/ 2 )
=-38.38236/90.584
=-42.37 %

where

Note: The Operating Income data used here is four times the quarterly (Dec. 2023) data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Evolus  (NAS:EOLS) ROIC % Explanation

ROIC % measures how well a company generates cash flow relative to the capital it has invested in its business. It is also called ROC %. The reason book values of debt and equity are used is because the book values are the capital the company received when issuing the debt or receiving the equity investments.

There are four key components to this definition. The first is the use of operating income or EBIT rather than net income in the numerator. The second is the tax adjustment to this operating income or EBIT, computed as a hypothetical tax based on an effective or marginal tax rate. The third is the use of book values for invested capital, rather than market values. The final is the timing difference; the capital invested is from the end of the prior year whereas the operating income or EBIT is the current year's number.

Why is ROIC % important?

Because it costs money to raise capital. A firm that generates higher returns on investment than it costs the company to raise the capital needed for that investment is earning excess returns. A firm that expects to continue generating positive excess returns on new investments in the future will see its value increase as growth increases, whereas a firm that earns returns that do not match up to its cost of capital will destroy value as it grows.

As of today, Evolus's WACC % is 11.80%. Evolus's ROIC % is -48.85% (calculated using TTM income statement data).


Be Aware

Like ROE % and ROA %, ROIC % is calculated with only 12 months of data. Fluctuations in the company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.


Evolus ROIC % Related Terms

Thank you for viewing the detailed overview of Evolus's ROIC % provided by GuruFocus.com. Please click on the following links to see related term pages.


Evolus (Evolus) Business Description

Traded in Other Exchanges
Address
520 Newport Center Drive, Suite 1200, Newport Beach, CA, USA, 92660
Evolus Inc is a performance beauty company with a customer-centric approach to delivering breakthrough products in the self-pay aesthetic market. The company's first commercial product is Jeuveau, a proprietary of 900 kilodalton, purified botulinum toxin type A formulation indicated for the temporary improvement in the appearance of moderate to severe glabellar lines, also known as frown lines, in adults. Its primary market is the self-pay aesthetic market, which includes medical products purchased by physicians and other customers that are then sold to consumers or used in procedures for aesthetic indications that are not reimbursed by any third-party payor, such as Medicaid, Medicare, or commercial insurance. It generates product revenue from the sale of Jeuveau in the United States.
Executives
David Moatazedi director, officer: See Remarks C/O OBALON THERAPEUTICS, INC., 5421 AVENIDA ENCINAS, SUITE F, CARLSBAD CA 92008
Medytox Inc. 10 percent owner 78, GANGNI 1-GIL, OCHANG-EUP,, CHEONGWON-GU, CHEOGJU-SI M5 28126
Sandra Beaver officer: Chief Financial Officer 520 NEWPORT CENTER DRIVE, SUITE 1200, NEWPORT BEACH CA 92660
Tomoko Yamagishi-dressler officer: Chief Marketing Officer 520 NEWPORT CENTER DRIVE, SUITE 1200, NEWPORT BEACH CA 92660
Rui Avelar officer: See Remarks 1618 STATION STREET, VANCOUVER A1 V6A 1B6
Vikram Malik director 17901 VON KARMAN AVENUE, SUITE 150, IRVINE CA 92614
Alphaeon 1 Llc 10 percent owner 4040 MACARTHUR BOULEVARD, SUITE 310, NEWPORT BEACH CA 92660
Robert Hayman director 8550 HIGUERA ST, CULVER CITY CA 90232
Simone Blank director C/O SIRONA, WASSERFELDSTRASSE 30 A-5020, SALZBURG C4 5020
Peter C Farrell director RESMED INC, 14040 DANIELSON STREET, POWAY CA 92064-6857
Lauren P Silvernail officer: See Remarks 15279 ALTON PARKWAY, SUITE #100, IRVINE CA 92618
David N Gill director C/O NXSTAGE MEDICAL INC. (NXTM), 439 SOUTH UNION STREET, 5TH FLOOR, LAWRENCE MA 01843
Crystal Muilenburg officer: Chief Marketing Officer 520 NEWPORT CENTER DRIVE, SUITE 1200, NEWPORT BEACH CA 92660
Brady Stewart director 520 NEWPORT CENTER DRIVE, SUITE 1200, NEWPORT BEACH CA 92660
Michael M. Jafar officer: Chief Marketing Officer 17901 VON KARMAN AVENUE, SUITE 150, IRVINE CA 92614